ADT1007-Abituzumab Biosimilar (ITGAV/CD5)-Research Biosimilar Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1007 |
Product Name |
ADT1007-Abituzumab Biosimilar (ITGAV/CD5)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names itgav antibody, cd51 antibody, itgav blocking antibody, cd51 blocking antibodies, anti-mouse cd51 antibody, anti-cd51 antibody, anti cd51 antibody, recombinant cd51, anti-cd51 monoclonal antibody, cd51 antibodies, cd51 recombinant antibody, itgav recombinant antibody |
|
Alias |
DI-17E6, EMD 525797, ITGAV, CD51, anti-ITGAV |
Host |
CHO Cells |
Species |
Human |
Target |
ITGAV /CD51 |
Gene ID |
3685 |
Isotype |
IgG2 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Cancer |
CAS Number |
1105038-73-0 |
Product Description |
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. |
Molecular Weight |
144.58 kDa
|
Application |
Inhibition, Agonist, ELISA, FACS, Functional Assay |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Tang YL, et al. BMC Pulm Med, 2022 Aug 4. PMID 35927660
2. Fu T, et al. Obes Facts, 2022. PMID 35320805
3. Kemper M, et al. J Exp Clin Cancer Res, 2021 Jun 26. PMID 34174926
|